Terms: = Uterine cancer AND CTNNB1, P35222, 1499, ENSG00000168036, CTNNB AND Treatment
51 results:
1. Proteogenomic insights into early-onset endometrioid endometrial carcinoma: predictors for fertility-sparing therapy response.
Hu Z; Wu Z; Liu W; Ning Y; Liu J; Ding W; Fan J; Cai S; Li Q; Li W; Yang X; Dou Y; Wang W; Peng W; Lu F; Zhuang X; Qin T; Kang X; Feng C; Xu Z; Lv Q; Wang Q; Wang C; Wang X; Wang Z; Wang J; Jiang J; Wang B; Mills GB; Ma D; Gao Q; Li K; Chen G; Chen X; Sun C
Nat Genet; 2024 Apr; 56(4):637-651. PubMed ID: 38565644
[TBL] [Abstract] [Full Text] [Related]
2. Integrated In-Silico and In Vitro analysis to Decipher the contribution of bisphenol-A in cervical cancer.
Khan NG; Adiga D; Rai PS; Kabekkodu SP
Toxicology; 2024 May; 504():153791. PubMed ID: 38555994
[TBL] [Abstract] [Full Text] [Related]
3. Detection of driver mutations and genomic signatures in endometrial cancers using artificial intelligence algorithms.
Stan A; Bosart K; Kaur M; Vo M; Escorcia W; Yoder RJ; Bouley RA; Petreaca RC
PLoS One; 2024; 19(2):e0299114. PubMed ID: 38408048
[TBL] [Abstract] [Full Text] [Related]
4. Deep molecular tracking over the 12-yr development of endometrial cancer from hyperplasia in a single patient.
Reid K; Camacho-Vanegas O; Pandya D; Camacho SC; Qiao RF; Kalir T; Padron-Rhenals MM; Beddoe AM; Dottino P; Martignetti JA
Cold Spring Harb Mol Case Stud; 2023 Dec; 9(4):. PubMed ID: 37848227
[TBL] [Abstract] [Full Text] [Related]
5. Proteogenomic insights suggest druggable pathways in endometrial carcinoma.
Dou Y; Katsnelson L; Gritsenko MA; Hu Y; Reva B; Hong R; Wang YT; Kolodziejczak I; Lu RJ; Tsai CF; Bu W; Liu W; Guo X; An E; Arend RC; Bavarva J; Chen L; Chu RK; Czekański A; Davoli T; Demicco EG; DeLair D; Devereaux K; Dhanasekaran SM; Dottino P; Dover B; Fillmore TL; Foxall M; Hermann CE; Hiltke T; Hostetter G; Jędryka M; Jewell SD; Johnson I; Kahn AG; Ku AT; Kumar-Sinha C; Kurzawa P; Lazar AJ; Lazcano R; Lei JT; Li Y; Liao Y; Lih TM; Lin TT; Martignetti JA; Masand RP; Matkowski R; McKerrow W; Mesri M; Monroe ME; Moon J; Moore RJ; Nestor MD; Newton C; Omelchenko T; Omenn GS; Payne SH; Petyuk VA; Robles AI; Rodriguez H; Ruggles KV; Rykunov D; Savage SR; Schepmoes AA; Shi T; Shi Z; Tan J; Taylor M; Thiagarajan M; Wang JM; Weitz KK; Wen B; Williams CM; Wu Y; Wyczalkowski MA; Yi X; Zhang X; Zhao R; Mutch D; Chinnaiyan AM; Smith RD; Nesvizhskii AI; Wang P; Wiznerowicz M; Ding L; Mani DR; Zhang H; Anderson ML; Rodland KD; Zhang B; Liu T; Fenyö D;
Cancer Cell; 2023 Sep; 41(9):1586-1605.e15. PubMed ID: 37567170
[TBL] [Abstract] [Full Text] [Related]
6. EZH2 activates Wnt/β-catenin signaling in human uterine fibroids, which is inhibited by the natural compound methyl jasmonate.
Ali M; Stone D; Laknaur A; Yang Q; Al-Hendy A
F S Sci; 2023 Aug; 4(3):239-256. PubMed ID: 37182601
[TBL] [Abstract] [Full Text] [Related]
7. Endometrioid Adenocarcinoma Resembling Cutaneous Pilomatrix Carcinoma: A Case Report of an Aggressive Neoplasm in a Young Woman With Diffusely Aberrant Beta-catenin Expression and Associated Morular Metaplasia and Atypical Polypoid Adenomyoma-type Change.
Keane E; Floyd R; McDonnell C; Beirne JP; Ó'Riain C; Komanyane L
Int J Gynecol Pathol; 2023 Sep; 42(5):466-471. PubMed ID: 36811845
[TBL] [Abstract] [Full Text] [Related]
8. Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry.
Vermij L; Jobsen JJ; León-Castillo A; Brinkhuis M; Roothaan S; Powell ME; de Boer SM; Khaw P; Mileshkin LR; Fyles A; Leary A; Genestie C; Jürgenliemk-Schulz IM; Crosbie EJ; Mackay HJ; Nijman HW; Nout RA; Smit VTHBM; Creutzberg CL; Horeweg N; Bosse T;
Br J Cancer; 2023 Mar; 128(7):1360-1368. PubMed ID: 36690721
[TBL] [Abstract] [Full Text] [Related]
9. Histopathological and molecular findings in 98 cases of endometrial carcinoma: MMR, p53 and next generation sequencing.
Karabağ S; Şentürk M; Söğüt FC; Ergül ÖS; Ersoy T
Pathol Res Pract; 2023 Jan; 241():154275. PubMed ID: 36528987
[TBL] [Abstract] [Full Text] [Related]
10. A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial cancer.
Konstantinopoulos PA; Lee EK; Xiong N; Krasner C; Campos S; Kolin DL; Liu JF; Horowitz N; Wright AA; Bouberhan S; Penson RT; Yeku O; Bowes B; Needham H; Hayes M; Sawyer H; Polak M; Shea M; Cheng SC; Castro C; Matulonis UA
J Clin Oncol; 2023 Jan; 41(3):599-608. PubMed ID: 36174113
[TBL] [Abstract] [Full Text] [Related]
11. The role of ctnnb1 mutations and matrix metalloproteinases (MMPs) in anti-angiogenesis treatment of endometrial carcinoma.
Berger AA; Kawaler EA; Dao F; Misirlioglu S; Fernandez EA; Olvera N; Van Oudenhove E; DeLair D; Levine DA
Gynecol Oncol; 2022 Nov; 167(2):323-333. PubMed ID: 36150916
[TBL] [Abstract] [Full Text] [Related]
12. Towards less invasive molecular diagnostics for endometrial cancer: massively parallel sequencing of endometrial lavage specimens in women attending for an office hysteroscopy.
Chao A; Wu KY; Lin CY; Lee YS; Huang HJ; Tang YH; Weng CH; Chao AS; Chang TC; Lai CH; Wu RC
J Mol Med (Berl); 2022 Sep; 100(9):1331-1339. PubMed ID: 35953603
[TBL] [Abstract] [Full Text] [Related]
13. Morules But Not Squamous Differentiation are a Reliable Indicator of ctnnb1 (β-catenin) Mutations in Endometrial Carcinoma and Precancers.
Niu S; Lucas E; Molberg K; Strickland A; Wang Y; Carrick K; Rivera-Colon G; Gwin K; SoRelle JA; Castrillon DH; Zheng W; Chen H
Am J Surg Pathol; 2022 Oct; 46(10):1447-1455. PubMed ID: 35834400
[TBL] [Abstract] [Full Text] [Related]
14. Adjuvant treatment in early-stage endometrial cancer: context-dependent impact of somatic
Kurnit KC; Fellman BM; Mills GB; Bowser JL; Xie S; Broaddus RR
Int J Gynecol Cancer; 2022 Jul; 32(7):869-874. PubMed ID: 35483739
[TBL] [Abstract] [Full Text] [Related]
15. Biomolecular and Genetic Prognostic Factors That Can Facilitate Fertility-Sparing treatment (FST) Decision Making in Early Stage Endometrial cancer (ES-EC): A Systematic Review.
Tanos P; Dimitriou S; Gullo G; Tanos V
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269800
[TBL] [Abstract] [Full Text] [Related]
16. Distinct Genomic Landscapes in Early-Onset and Late-Onset Endometrial cancer.
Choi J; Holowatyj AN; Du M; Chen Z; Wen W; Schultz N; Lipworth L; Guo X
JCO Precis Oncol; 2022 Feb; 6():e2100401. PubMed ID: 35108035
[TBL] [Abstract] [Full Text] [Related]
17. Prognostic significance of ctnnb1 mutation in early stage endometrial carcinoma: a systematic review and meta-analysis.
Travaglino A; Raffone A; Raimondo D; Reppuccia S; Ruggiero A; Arena A; Casadio P; Zullo F; Insabato L; Seracchioli R; Mollo A
Arch Gynecol Obstet; 2022 Aug; 306(2):423-431. PubMed ID: 35034160
[TBL] [Abstract] [Full Text] [Related]
18. Inhibiting Wnt/beta-catenin in ctnnb1-mutated endometrial cancer.
Moroney MR; Woodruff E; Qamar L; Bradford AP; Wolsky R; Bitler BG; Corr BR
Mol Carcinog; 2021 Aug; 60(8):511-523. PubMed ID: 34038589
[TBL] [Abstract] [Full Text] [Related]
19. Identification of a Gene Panel for Endometrioid Endometrial cancer: a Possible Prognostic Value?
Malentacchi F; Turrini I; Sorbi F; Projetto E; Castiglione F; Vergoni F; Amunni G; Fambrini M; Petraglia F; Noci I; Pillozzi S
Reprod Sci; 2020 Feb; 27(2):592-598. PubMed ID: 32046431
[TBL] [Abstract] [Full Text] [Related]
20. Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86).
Dhani NC; Hirte HW; Wang L; Burnier JV; Jain A; Butler MO; Welch S; Fleming GF; Hurteau J; Matsuo K; Matei D; Jimenez W; Johnston C; Cristea M; Tonkin K; Ghatage P; Lheureux S; Mehta A; Quintos J; Tan Q; Kamel-Reid S; Ludkovski O; Tsao MS; Wright JJ; Oza AM
Clin Cancer Res; 2020 Jun; 26(11):2477-2486. PubMed ID: 31992589
[TBL] [Abstract] [Full Text] [Related]
[Next]
